These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28613975)

  • 1. Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death.
    Leng ZG; Lin SJ; Wu ZR; Guo YH; Cai L; Shang HB; Tang H; Xue YJ; Lou MQ; Zhao W; Le WD; Zhao WG; Zhang X; Wu ZB
    Autophagy; 2017 Aug; 13(8):1404-1419. PubMed ID: 28613975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of dopamine receptor subtypes DRD2 and DRD5 in drug therapy of pituitary tumors].
    Liu YT; Zhang Y; Wang Y; Wu ZB
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(22):1703-1706. PubMed ID: 31216815
    [No Abstract]   [Full Text] [Related]  

  • 3. Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine.
    Lin SJ; Wu ZR; Cao L; Zhang Y; Leng ZG; Guo YH; Shang HB; Zhao WG; Zhang X; Wu ZB
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3692-3703. PubMed ID: 28973192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline.
    Lin SJ; Leng ZG; Guo YH; Cai L; Cai Y; Li N; Shang HB; Le WD; Zhao WG; Wu ZB
    Oncotarget; 2015 Nov; 6(36):39329-41. PubMed ID: 26513171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma.
    Yao H; Tang H; Zhang Y; Zhang QF; Liu XY; Liu YT; Gu WT; Zheng YZ; Shang HB; Wang Y; Huang JY; Wei YX; Zhang X; Zhang J; Wu ZB
    Cancer Lett; 2019 Sep; 459():135-144. PubMed ID: 31176743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
    Tang C; Sun R; Wen G; Zhong C; Yang J; Zhu J; Cong Z; Luo X; Ma C
    Cell Death Dis; 2019 Apr; 10(5):335. PubMed ID: 31000722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.
    Prabhu VV; Madhukar NS; Gilvary C; Kline CLB; Oster S; El-Deiry WS; Elemento O; Doherty F; VanEngelenburg A; Durrant J; Tarapore RS; Deacon S; Charter N; Jung J; Park DM; Gilbert MR; Rusert J; Wechsler-Reya R; Arrillaga-Romany I; Batchelor TT; Wen PY; Oster W; Allen JE
    Clin Cancer Res; 2019 Apr; 25(7):2305-2313. PubMed ID: 30559168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway.
    Jiang B; Wang F; Yang S; Fang P; Deng ZF; Xiao JL; Hu ZL; Chen JG
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of dopamine receptor D1 inhibits glioblastoma tumorigenicity by regulating autophagic activity.
    Yang K; Wei M; Yang Z; Fu Z; Xu R; Cheng C; Chen X; Chen S; Dammer E; Le W
    Cell Oncol (Dordr); 2020 Dec; 43(6):1175-1190. PubMed ID: 32761562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteoloside induces G
    Zhou M; Shen S; Zhao X; Gong X
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):263-269. PubMed ID: 29024631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways.
    Zhu J; Tang C; Cong Z; Yuan F; Cai X; Yang J; Ma C
    Endocr Relat Cancer; 2021 Dec; 29(2):33-46. PubMed ID: 34821219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D
    Lee H; Jiang X; Perwaiz I; Yu P; Wang J; Wang Y; Hüttemann M; Felder RA; Sibley DR; Polster BM; Rozyyev S; Armando I; Yang Z; Qu P; Jose PA
    Hypertens Res; 2021 Jun; 44(6):628-641. PubMed ID: 33820956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric modulation of sigma-1 receptors by SKF83959 inhibits microglia-mediated inflammation.
    Wu Z; Li L; Zheng LT; Xu Z; Guo L; Zhen X
    J Neurochem; 2015 Sep; 134(5):904-14. PubMed ID: 26031312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine.
    Li Q; Su Z; Liu J; Cai L; Lu J; Lin S; Xiong Z; Li W; Zheng W; Wu J; Zhuge Q; Wu Z
    Mol Cell Endocrinol; 2014 Jan; 382(1):377-384. PubMed ID: 24184771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
    Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
    J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas.
    Zhang D; Way JS; Zhang X; Sergey M; Bergsneider M; Wang MB; Yong WH; Heaney AP
    J Clin Endocrinol Metab; 2019 Jun; 104(6):1929-1936. PubMed ID: 30624667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
    Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a fluorescent small-molecule enhancer for therapeutic autophagy in colorectal cancer by targeting mitochondrial protein translocase TIM44.
    Huang Y; Zhou J; Luo S; Wang Y; He J; Luo P; Chen Z; Liu T; Tan X; Ou J; Miao H; Liang H; Shi C
    Gut; 2018 Feb; 67(2):307-319. PubMed ID: 27849558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.